CRISPR/Cas9 is making gene-editing cheaper and easier than ever before, but the creators are embroiled in a fierce dispute over who holds the patents to CRISPR technology. In this episode, after hearing attorneys duke it out, Ryan Cross explains how the kerfuffle developed, and what the possible outcomes of the impending decision mean.
The Legal Battle Over CRISPR
The lowdown on the CRISPR gene-editing patent dispute at the U.S. Patent & Trademark Office.
Jan 10, 2017
Latest in Chemical Processing
Jury Awards $332 Million to Man in Monsanto Case
November 3, 2023
EPA Boosts Biofuel Requirements
June 22, 2023
Bayer Owes $6.9M Over Weed Killer Advertising
June 16, 2023
50-Car Train Derailment Causes Big Fire, Evacuations
February 6, 2023